$RMD News

Rothschild & Co Initiates Coverage of ResMed (RMD) with Neutral Recommendation

Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230

Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor

ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles

The 5 Most Interesting Analyst Questions From ResMed’s Q2 Earnings Call

ResMed (RMD) Q4 2026 Earnings Call Transcript

ResMed (RMD) Stock May Be 31% Undervalued After Soft FY27 Outlook

Is Recall-Hit Outlook and Bigger Payout Altering The Investment Case For ResMed (RMD)?

Resmed’s stock falls by 7% on soft FY27 outlook

RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts

RBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244

RMD Stock Down Despite Q4 Earnings Beat, Revenues Rise Y/Y

Piper Sandler Maintains Neutral on ResMed, Lowers Price Target to $225

ResMed Shares Fall After Revenue Miss and Conservative 2027 Outlook

Keybanc Maintains Overweight on ResMed, Lowers Price Target to $255

Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215

ResMed Inc (RMD) (Q4 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

ResMed Inc. (RMD) Q4 2026 Earnings Call Transcript

ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops

ResMed (RMD) Q4 Earnings and Revenues Top Estimates